Menu
Search
|

Menu

Close
X

Depomed Inc DEPO.OQ (NASDAQ Stock Exchange Global Select Market)

7.44 USD
-- (--)
As of Feb 17
chart
Previous Close 7.44
Open --
Volume --
3m Avg Volume 399,202
Today’s High --
Today’s Low --
52 Week High 17.85
52 Week Low 4.32
Shares Outstanding (mil) 62.99
Market Capitalization (mil) 369.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
286
FY16
456
FY15
343
EPS (USD)
FY17
-1.111
FY16
-1.445
FY15
-1.258
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
0.87
5.77
Price to Book (MRQ)
vs sector
1.75
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
300.41
16.52
LT Debt to Equity (MRQ)
vs sector
273.21
12.22
Return on Investment (TTM)
vs sector
-12.06
14.43
Return on Equity (TTM)
vs sector
-43.53
16.13

EXECUTIVE LEADERSHIP

James Fogarty
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Arthur Higgins
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
August Moretti
Chief Financial Officer, Senior Vice President, Since 2016
Salary: $418,820.00
Bonus: --
Santosh Vetticaden
Senior Vice President, Chief Medical and Scientific Officer, Since 2017
Salary: --
Bonus: --
Matthew Gosling
Senior Vice President, General Counsel, Since 2011
Salary: $470,833.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

7999 Gateway Blvd Ste 300
NEWARK   CA   94560-1188

Phone: +1510.7448000

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

SPONSORED STORIES